About 3sbio inc. - TRSBF
3SBio, Inc. operates as an investment holding company, which engages in the development, production, marketing, and sale of biopharmaceutical products. Its products are used in the field of medicine, particularly in nephrology, oncology, supportive cancer care, inflammation, and infectious diseases. It operates through the Mainland China and Others geographical segments. The company was founded by Jing Lou and Dan Lou in 1993 and is headquartered in Shenyang, China.
TRSBF At a Glance
3SBio, Inc.
Shenyang Economy & Tech Development
Shenyang, Liaoning 110027
| Phone | 86-24-25386000 | Revenue | 1.27B | |
| Industry | Biotechnology | Net Income | 290.45M | |
| Sector | Health Technology | 2024 Sales Growth | 14.721% | |
| Fiscal Year-end | 12 / 2025 | Employees | 5,577 | |
| View SEC Filings |
TRSBF Valuation
| P/E Current | 32.554 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 6.533 |
| Price to Sales Ratio | 1.526 |
| Price to Book Ratio | 0.872 |
| Price to Cash Flow Ratio | 3.926 |
| Enterprise Value to EBITDA | 4.437 |
| Enterprise Value to Sales | 1.488 |
| Total Debt to Enterprise Value | 0.259 |
TRSBF Efficiency
| Revenue/Employee | 226,924.211 |
| Income Per Employee | 52,080.079 |
| Receivables Turnover | 7.078 |
| Total Asset Turnover | 0.381 |
TRSBF Liquidity
| Current Ratio | 1.711 |
| Quick Ratio | 1.565 |
| Cash Ratio | 1.189 |
TRSBF Profitability
| Gross Margin | 85.951 |
| Operating Margin | 29.019 |
| Pretax Margin | 26.012 |
| Net Margin | 22.95 |
| Return on Assets | 8.738 |
| Return on Equity | 14.191 |
| Return on Total Capital | 11.164 |
| Return on Invested Capital | 12.949 |
TRSBF Capital Structure
| Total Debt to Total Equity | 23.026 |
| Total Debt to Total Capital | 18.717 |
| Total Debt to Total Assets | 14.68 |
| Long-Term Debt to Equity | 0.449 |
| Long-Term Debt to Total Capital | 0.365 |